(Reuters) -Pfizer (PFE) said on Monday it would acquire weight-loss drug developer Metsera (MTSR) in a deal valued at up to $7.3 billion, including future payments, to secure its position in the lucrative obesity treatment market. The global obesity drug market, projected to reach$150 billion by early 2030s, has been booming over the last few years, driven by the success of highly effective GLP-1-targeting therapies from companies such as Novo Nordisk (NVO, NOVO-B.CO) and Eli Lilly (LLY) — both fiercely ...